A next-generation BH3 toolkit aims to deliver durable apoptotic control in acute myeloid leukemia (AML) while mitigating the class-defining liabilities of thrombocytopenia from BCL-XL antagonism and cardiotoxicity from sustained MCL-1 suppression (Table 4). Here, BCL2L1 is linked to acute myeloid leukemia.